PASylation^® provides an enabling technology with a unique combination of benefits for superior next generation biopharmaceuticals. Apart from conventional therapeutic proteins, such as growth factors, hormones, and cytokines, PASylation^® can boost the exploration of novel classes of small biopharmaceuticals suffering from a short plasma half-life, e.g. antibody fragments, single chain/domain antibodies, alternative scaffolds, and even peptides. In addition, PASylation^® offers opportunities for the life cycle management of approved biologicals whose patent protection is going to expire.

To uncover the full potential of the PASylation^® technology XL-protein^® offers collaborations with pharmaceutical, biogeneric, and biotech companies on the following levels.

• Out-licensing of our proprietary PASylation^® technology for defined protein classes or disease areas.
• Out-licensing of XL-protein’s proprietary product candidates.
• Co-development of new, innovative protein drugs.
• In-licensing of interesting therapeutic proteins which could benefit from the PASylation^® technology.